Cargando…
Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial
Antitumor activity in preclinical models and a phase I study of patients with dedifferentiated liposarcoma (DD-LPS) was observed with selinexor. We evaluated the clinical benefit of selinexor in patients with previously treated DD-LPS whose sarcoma progressed on approved agents. METHODS: SEAL was a...
Ejemplares similares
-
Health-related quality of life and pain with selinexor in patients with advanced dedifferentiated liposarcoma
por: Gounder, Mrinal, et al.
Publicado: (2021) -
Preclinical activity of selinexor in combination with eribulin in uterine leiomyosarcoma
por: Mittal, Sonam, et al.
Publicado: (2023) -
Selinexor Overcomes Hypoxia-Induced Drug Resistance in Multiple Myeloma
por: Muz, Barbara, et al.
Publicado: (2017) -
PB2106: REAL-WORLD SAFETY AND EFFECTIVENESS OF SELINEXOR-BASED REGIMENS IN PATIENTS WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA AND DIALYSIS-DEPENDENT RENAL IMPAIRMENT
por: Niblock, James, et al.
Publicado: (2023) -
Overview of systemic therapy options in liposarcoma, with a focus on the activity of selinexor, a selective inhibitor of nuclear export in dedifferentiated liposarcoma
por: Thirasastr, Prapassorn, et al.
Publicado: (2022)